These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9477172)

  • 1. Polymer blend implant for ocular delivery of fluorometholone.
    Morita Y; Saino H; Tojo K
    Biol Pharm Bull; 1998 Jan; 21(1):72-5. PubMed ID: 9477172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreous delivery of dexamethasone sodium m-sulfobenzoate from poly(DL-lactic acid) implants.
    Morita Y; Ohtori A; Kimura M; Tojo K
    Biol Pharm Bull; 1998 Feb; 21(2):188-90. PubMed ID: 9514619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of fluorometholone-loaded PLGA nanoparticles for treatment of inflammatory disorders of anterior and posterior segments of the eye.
    Gonzalez-Pizarro R; Silva-Abreu M; Calpena AC; Egea MA; Espina M; García ML
    Int J Pharm; 2018 Aug; 547(1-2):338-346. PubMed ID: 29800741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel design of one-side coated biodegradable intrascleral implant for the sustained release of triamcinolone acetonide.
    Kim YM; Lim JO; Kim HK; Kim SY; Shin JP
    Eur J Pharm Biopharm; 2008 Sep; 70(1):179-86. PubMed ID: 18667297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biocompatibility and Pharmacokinetic Analysis of an Intracameral Polycaprolactone Drug Delivery Implant for Glaucoma.
    Kim J; Kudisch M; Mudumba S; Asada H; Aya-Shibuya E; Bhisitkul RB; Desai TA
    Invest Ophthalmol Vis Sci; 2016 Aug; 57(10):4341-6. PubMed ID: 27556217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biodegradable chitosan and polylactic acid-based intraocular micro-implant for sustained release of methotrexate into vitreous: analysis of pharmacokinetics and toxicity in rabbit eyes.
    Manna S; Banerjee RK; Augsburger JJ; Al-Rjoub MF; Donnell A; Correa ZM
    Graefes Arch Clin Exp Ophthalmol; 2015 Aug; 253(8):1297-305. PubMed ID: 25896109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scleral plug of biodegradable polymers containing tacrolimus (FK506) for experimental uveitis.
    Sakurai E; Nozaki M; Okabe K; Kunou N; Kimura H; Ogura Y
    Invest Ophthalmol Vis Sci; 2003 Nov; 44(11):4845-52. PubMed ID: 14578407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PLA/F68/dexamethasone implants prepared by hot-melt extrusion for controlled release of anti-inflammatory drug to implantable medical devices: I. Preparation, characterization and hydrolytic degradation study.
    Li D; Guo G; Fan R; Liang J; Deng X; Luo F; Qian Z
    Int J Pharm; 2013 Jan; 441(1-2):365-72. PubMed ID: 23178216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocular Physiologically Based Pharmacokinetic Modeling for Ointment Formulations.
    Le Merdy M; Spires J; Lukacova V; Tan ML; Babiskin A; Xu X; Zhao L; Bolger MB
    Pharm Res; 2020 Nov; 37(12):245. PubMed ID: 33215336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modified PLA nano in situ gel: a potential ophthalmic drug delivery system.
    Nagarwal RC; Kumar R; Dhanawat M; Pandit JK
    Colloids Surf B Biointerfaces; 2011 Aug; 86(1):28-34. PubMed ID: 21497491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-situ forming gels containing fluorometholone-loaded polymeric nanoparticles for ocular inflammatory conditions.
    Gonzalez-Pizarro R; Carvajal-Vidal P; Halbault Bellowa L; Calpena AC; Espina M; García ML
    Colloids Surf B Biointerfaces; 2019 Mar; 175():365-374. PubMed ID: 30554015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal delivery of ciprofloxacin.
    Hainsworth DP; Conklin JD; Bierly JR; Ax D; Ashton P
    J Ocul Pharmacol Ther; 1996; 12(2):183-91. PubMed ID: 8773934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fabrication, implantation, elution, and retrieval of a steroid-loaded polycaprolactone subretinal implant.
    Beeley NR; Rossi JV; Mello-Filho PA; Mahmoud MI; Fujii GY; de Juan E; Varner SE
    J Biomed Mater Res A; 2005 Jun; 73(4):437-44. PubMed ID: 15900615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. General Pharmacokinetic Model for Topically Administered Ocular Drug Dosage Forms.
    Deng F; Ranta VP; Kidron H; Urtti A
    Pharm Res; 2016 Nov; 33(11):2680-90. PubMed ID: 27431864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of drug delivery to the posterior pole of the rabbit eye with an episcleral implant.
    Kato A; Kimura H; Okabe K; Okabe J; Kunou N; Ogura Y
    Invest Ophthalmol Vis Sci; 2004 Jan; 45(1):238-44. PubMed ID: 14691179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin drug delivery system for prevention of posterior capsular opacification in rabbit eyes.
    Xie L; Sun J; Yao Z
    Graefes Arch Clin Exp Ophthalmol; 2003 Apr; 241(4):309-13. PubMed ID: 12719992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ophthalmic bioequivalence of steroid/antibiotic combination formulations.
    Schoenwald RD; Harris RG; Turner D; Knowles W; Chien DS
    Biopharm Drug Dispos; 1987; 8(6):527-48. PubMed ID: 3427210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging.
    Kim H; Robinson MR; Lizak MJ; Tansey G; Lutz RJ; Yuan P; Wang NS; Csaky KG
    Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2722-31. PubMed ID: 15277497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new vitreal drug delivery system using an implantable biodegradable polymeric device.
    Kimura H; Ogura Y; Hashizoe M; Nishiwaki H; Honda Y; Ikada Y
    Invest Ophthalmol Vis Sci; 1994 May; 35(6):2815-9. PubMed ID: 8188476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel in situ forming drug delivery system for controlled parenteral drug delivery.
    Kranz H; Bodmeier R
    Int J Pharm; 2007 Mar; 332(1-2):107-14. PubMed ID: 17084049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.